1. Home
  2. PCSA vs UCAR Comparison

PCSA vs UCAR Comparison

Compare PCSA & UCAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$3.56

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$1.50

Market Cap

9.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCSA
UCAR
Founded
2011
2013
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail-Auto Dealers and Gas Stations
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.0M
9.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
PCSA
UCAR
Price
$3.56
$1.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$25.00
$5.00
AVG Volume (30 Days)
321.0K
16.1K
Earning Date
11-06-2025
10-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,816,075.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
57.22
52 Week Low
$2.74
$1.40
52 Week High
$22.80
$9.43

Technical Indicators

Market Signals
Indicator
PCSA
UCAR
Relative Strength Index (RSI) 59.91 42.91
Support Level $3.07 $1.46
Resistance Level $3.80 $1.62
Average True Range (ATR) 0.31 0.10
MACD -0.08 0.01
Stochastic Oscillator 67.27 38.13

Price Performance

Historical Comparison
PCSA
UCAR

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

Share on Social Networks: